For our office in Hamburg, we are looking for dedicated
Working Student for Internal Audit (all genders)
Part time and fixed term (6 months)
Key responsibilities:
Perform testing of SOX controls, including walkthroughs, design testing and assessment of operational effectiveness
Identify control and process deficiencies as well as improvement opportunities
Communicate effectively with finance and non-finance stakeholders on the importance of controls, a strong control environment and the role of audit related improvements
Support additional audit-related projects as required
Qualifications:
Currently enrolled student in Accounting, Audit, Finance, Economics or a related field
Fluent in English (spoken and written); additional languages are a plus
Strong analytical and communication skills and the ability to work with diverse stakeholders
Reliable, structured and detail-oriented working style
High motivation, willingness to learn and team-oriented mindset
Good understanding of internal control requirements, accounting processes and audit practices
Solid MS Office skills (Word, Excel, PowerPoint)
First experience with Sarbanes-Oxley (SOX) is a plus
Our Offer:
A position as a working student in a friendly and engaging team, promoted by an open company culture
A diverse, highly international workforce in an environment that fosters creativity, innovations and teamwork
Flexible hours
Competitive payment
FR : Dans le cadre de sa politique Diversité, Evotec étudie, à compétences égales, toutes les candidatures dont celles des personnes en situation de handicap.
ENG : In the frame of our Diversity policy, Evotec considers, with equal competences, all applications including people with disabilities.
Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients.
Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing.
We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI.
We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.
